Lantheus is a global leader in the field of medical imaging. We develop, manufacture and commercialize essential diagnostic imaging agents and products that help healthcare professionals identify disease and improve patient treatment and care. Our pioneering products assist physicians in the diagnosis of conditions affecting the heart, brain, lungs and other organs using echocardiography, nuclear imaging and magnetic resonance imaging (MRI) technologies.
Our products are routinely used to diagnose coronary artery disease (CAD), congestive heart failure (CHF), stroke, peripheral vascular (PVD) and other diseases.
In addition to our diversified portfolio of commercialized imaging agents and products, we have a strong development pipeline of internally-discovered next generation, first-in-class imaging agents that use positron emission tomography (PET), MRI technologies focused on enhancing current imaging modalities and fulfilling unmet diagnostic medical imaging needs.
Closing share price
|FY, 2013||FY, 2014|
|$283.7 m||$301.6 m|
Revenue growth, %
|($61.7 m)||($1.2 m)|